NRX Pharmaceuticals (NRXP) Intangibles (2025 - 2026)

NRX Pharmaceuticals (NRXP) posted quarterly Intangibles of $879000.0 for Q1 2026, down 4.97% quarter-over-quarter from $925000.0 in Q4 2025.

NRX Pharmaceuticals (NRXP) Intangibles (2025 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has reported Intangibles for 2 consecutive years, with $879000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Intangibles changed N/A year-over-year to $879000.0; the TTM figure through Mar 2026 stood at $879000.0 (changed N/A YoY), while the FY2025 annual figure was $925000.0, changed N/A from the prior year.
Intangibles retreated to $879000.0 in Q1 2026 per NRXP's latest filing, from $925000.0 in the prior quarter.
Across five years, Intangibles topped out at $1.8 million in Q3 2025 and bottomed at $879000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	412.80 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.31 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	266.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	60.96 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	93.49 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	NRX Pharmaceuticals	132.53 Mn	105.83 Mn	426,000.00	832,000.00

Download Data